Tau is the most abundant microtubule-associated protein in the brain .If tau protein lost the normal function, the toxic effect should be showed and plays an important role in various central nervous system lesions .Hypoxic-ischemic encephalopathy ( HIE) is an important cause of mortality in the neonatal period and it is mainly characterized by neurological deficits such as cognitive limitations .However , the mechanism still needs further study , and the underlying re-lationship between tau protein and HIE lacks direct evidence .Some recent clinical study reported that tau protein expres-sion elevated in the serum of asphyxia children and had a high correlation with behavior deficient .In this review , we focus on 3 key points to provide new insights to understand the tau protein-related pathogenesis of HIE as followed:(1) tau pro-tein and its phosphorylation change during central nervous system development ;(2) comparison of tau protein expression in developing brain and adult brain under some neurological disorders;(3) potential pathological change of tau in HIE related pathological conditions , such as dysmyelination , inflammation response and glutamate metabolism .

MicroRNAs can post-transcriptionally regulate the expression of their target mRNAs. MicroRNA-126 plays an important role in tumorigeness by targeting EGFL7, HOXA9, IRS-1 and p85-β. Intriguingly, it is downregulated in a wide range of tumors and is testified that it functions as a tumor suppressor in lung cancer, leukemia, breast cancer and ovarian cancer.

Objective To investigate the clinical effect of methylprednisolone and aminophylline on bronchial asthma patients, so as to improve the level of clinical treatment. Methods Selected form August 2014 to June 2016 in our hospital diagnosed with bronchial asthma in 90 patients as the research object, for the normal group and the treatment group in accordance with the double blind method standard for sharing, the former the latter with aminophylline treatment; Methylprednisolone Treatment on the basis of the former treatment. After treatment, the statistical comparison of two groups and the clinical symptoms and quality of life to improve the situation. Results the total efficiency of the treatment group was 97.8％, significantly higher than that of the control group 77.8％(P<0.05). The treatment group of clinical symptoms and signs scores were lower than those of the reference group; improving the quality of life was better than the reference group, there were significant differences between groups of data comparison, statistical significance was established(P<0.05). Conclusion Patients with bronchial asthma by aminophylline combined with methylprednisolone treatment, the effect is considerable, not only can improve the treatment effect, rapidly relieve symptoms, improve the quality of life of patients, suggest further promotion.

OBJECTIVE: To study the effect of salvianolate on the migration of endothelial cells induced by monocytes. METHODS: Transwell-boydom system was used to test the migration of endothelial cells induced by monocytes. Enzyme-linked immunosorbent assay (ELISA) and RT-polymerase chain reaction (RT-PCR) method were used to determine the effect of salvianolate on the expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and their mRNA of monocytes. RESULTS: The migration of endothelial cells induced by monocytes was facilitated by salvianolate, compared with the control. After the monocytes were treated by salvianolate for 24 hours, the expression of mRNA of VEGF and bFGF was significantly up-regulated, and the expression of VEGF and bFGF was increased. CONCLUSION: The facilitation of salvianolate on the migration of endothelial cells induced by monocytes was observed. Salvianolate stimulates the expression of VEGF and bFGF and their mRNA of monocytes, and salvianolate may have the role of inducing migration of endothelial cells by working on these two factors.

In order to study the physiological action of glucocorticoid receptor (GR) in intact animal, an animal model of GR depletion was developed in the rat by mifepristone (RU486), an antagonist of GR. Mifepristone 50 mg/kg body weight mixed in polyvinyl alcohol (PVA) was injected intramuscularly every 12 h in order to maintain the plasma mifepristone at the concentration of about 10-6mol/L for 72 h. In the meanwhile, the plasma corticosterone (B) was stabilized at about 15 ?g/dl by unilateral adrenalectomy 3 d before. In this model mifepristone occupied 88.1 ?10.7% of the total GR in hepatic, brain cytosol and thymocytes as measured by the exchange assay with [3H]dexamethasone (Dex) as ligand. Some indexes of glucocorticoid response were measured in the control, model and bilateral adrenalectomized (AdxT) rats. The polymorphonuclear eosinophil leukocyte (PME) count in blood and phospholipase A2(PLA2) activity in serum were decreased and tyrosine aminotransferase (TAT) activity of the liver was elevated in the control rats after stress provoked by epinephrine, but these changes were reversed in the model rats as well as in the AdxT rats. Thus it may be concluded that decrease of GR to about 12% may result in adrenoglucocorticoid insufficiency in spite of the normal functioning adrenal gland and high plasma level of B. So far as we know this is the first success to produce experimental endocrine insufficiency in a receptor depletion animal model and to quantitate the occupational threshold of about 12% of the total GR in rats.

Although dyslipidemia is common in the patients with end-stage renal disease undergoing dialysis, it is still controver-sial in the efficacy and safety of lipid-modulating agents used in the patients. In this paper, current large-scale randomized controlled trials and observational studies were reviewed, and the influence and characteristics of dyslipidemia as well as the application of com-mon lipid-modulating agents in dialysis patients were summarized. The current clinical evidence suggested that the use of statins with or without ezetimibe could effectively reduce the level of blood lipid in dialysis patients without increased risk of adverse events, while it had limited role in cardiovascular protection;fibrates had higher risks in dialysis patients; nicotinic acids had limited use mainly be-cause of their unbearable side effects.

Animals ; Brain Ischemia ; metabolism ; Hippocampus ; drug effects ; metabolism ; Male ; Nitric Oxide Synthase Type II ; metabolism ; Propofol ; pharmacology ; Rats ; Rats, Wistar ; Reperfusion Injury ; metabolism

Female ; Hepatitis C ; complications ; drug therapy ; Humans ; Interferon-alpha ; therapeutic use ; Interferons ; therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; complications ; drug therapy ; virology ; Middle Aged ; Polyethylene Glycols ; therapeutic use ; Recombinant Proteins ; therapeutic use ; Treatment Outcome

The Epstein-Barr virus (EBV) has been demonstrated to be associated with several human tumors, including nasopharyngeal carcinoma (NPC), Burkitt's lymphoma (BL), post-transplant lymphoproliferative disease (PTLD), Hodgkin's lymphoma (HL), non-Hodgkin's lymphomas (NHL) and gastric cancer (GC). In most EBV-associated malignancies, the tumor cells contain the viral genome. This provides a unique opportunity to develop therapeutic strategies utilizing the viral genome of EBV as a potential drug target. This review focuses on different therapeutic strategies against EBV-associated malignancies, further discusses the possible therapeutic approach using drug-induced virus activation and its certain pathways. Copyright © 2014 by TUMOR.

Objective This study aims to observe and analyze the result of implementing health management and intervention for chronic Keshan disease treatment. Methods Certain amounts of chronic Keshan disease patients in Keshan disease area were chosen and given health management and treatment intervention including primarily pharmacological treatment for the chronic congestive heart failure together with health education and life style instruction. From 2006 to 2008, three interventions were conducted every six month. Electrocardiogram description, proportion of heart to chest, classification of heart function, types of Keshan disease and labour capacity at the initial and the last stage of the intervention were taken as judging indexes. If one of the indexes was improved then the intervention will be regarded as effective. The number of effective cases and effective rate were counted in order to observe the impact of intervention times and different medicine on intervention results. Results Altogether 345 Keshan disease patients were involved in the study, among them 207 were effective, the effective rate was 60%(207/345). One hundred and eighty were involved in the intervention for once, and the effective rate was 44%(79/180). Ninty-one took part in the intervention twice, and the effective rate was 66%(60/91). Seventyfour attended the intervention for three times, and the effective rate was 92% (68/74). There were significant difference among groups of different intervention times (χ2 = 52.16, P < 0.01), and the effective rate increased with increased intervention times. Three times were higher than that of one or two times (χ2= 15.81, 49.56, all P< 0.0125). Twice were better than once(χ2 = 11.76, P < 0.0125). There were significant difference among groups of different medicine groups(χ2 = 19.56, P< 0.01). Among different medicine groups, the efficacy of angiotensin converting enzyme inhibitor(ACEI) group was the highest 77%(82/106) while the cardiotonic medicine group was 50%(47/94) and cardiac muscle nutrition poisons was 54% (78/145). The efficacy rate of ACEI group was higher than that of cardiotonic medicine group and cardiac muscle nutrition poisons(χ2 = 16.28, 14.71, P< 0.0125). Conclusions The implement of health management and treatment intervention to Keshan disease patients is of great significant in improving the healthy condition of Keshan disease patients. Health education and life-style instruction as well as the use of ACEI, β-blockers and diuretic have comparatively obvious effect on treatment of chronic Keshan disease congestive cardiac failure.